RET Mutation

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Thyroid Gland Neoplasm2
v::RET Fusion OR RET Mutation	Pralsetinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11267 In this multi-cohort, open-label, phase 1/2 study, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were started on pralsetinib dosed at 400 mg once daily. Overal… (full text at CIViC) PMID 34118198 · Subbiah et al., 2021 · Open in CIViC	civic
v::RET Fusion OR RET Mutation	Selpercatinib	Predictive	A	Supports Sensitivity Response	4	rejected	EID11268 In this phase 1/2 study, 55 patients with RET-mutant medullary thyroid cancer who had previously received vandetanib and/or cabozantinib, 88 patients with the same disease who had not previously recei… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Malignant Thyroid Gland Neoplasm2

v::RET Fusion OR RET Mutation

Pralsetinib

Predictive

Supports Sensitivity Response

submitted

EID11267

In this multi-cohort, open-label, phase 1/2 study, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were started on pralsetinib dosed at 400 mg once daily. Overal… (full text at CIViC)

PMID 34118198 · Subbiah et al., 2021 · Open in CIViC

civic

v::RET Fusion OR RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

rejected

EID11268

In this phase 1/2 study, 55 patients with RET-mutant medullary thyroid cancer who had previously received vandetanib and/or cabozantinib, 88 patients with the same disease who had not previously recei… (full text at CIViC)

PMID 32846061 · Wirth et al., 2020 · Open in CIViC

Solid Neoplasm2
v::RET Fusion OR RET Mutation	Selpercatinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID12056 As part of this trial, 27 pediatric patients (aged 2-20), harbouring, RET-mutant medullary thyroid cancer (MTC, n = 14), RET fusion-positive papillary thyroid cancer (RTC, n=10), or other tumour types… (full text at CIViC) Open in CIViC	civic
v::RET Fusion OR RET Mutation	Selpercatinib	Predictive	A	Supports Sensitivity Response	5	accepted	EID12708 In the phase 1/2 trial LIBRETTO-121 (NCT03899792), for patients 0.5-21 yrs old with advanced RET-altered solid tumors, dosing started at 92 mg/m2 twice a day of Selpercatinib. Patients had RET-mutant… (full text at CIViC) Open in CIViC	civic

Solid Neoplasm2

v::RET Fusion OR RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID12056

As part of this trial, 27 pediatric patients (aged 2-20), harbouring, RET-mutant medullary thyroid cancer (MTC, n = 14), RET fusion-positive papillary thyroid cancer (RTC, n=10), or other tumour types… (full text at CIViC)

Open in CIViC

civic

v::RET Fusion OR RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID12708

In the phase 1/2 trial LIBRETTO-121 (NCT03899792), for patients 0.5-21 yrs old with advanced RET-altered solid tumors, dosing started at 92 mg/m2 twice a day of Selpercatinib. Patients had RET-mutant… (full text at CIViC)

Open in CIViC

civic

Thyroid Gland Carcinoma1
RET Mutation	NVP-AST487 + SapanisertibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID4854 The objective of this preclinical study was to investigate the contribution of mTOR activity to RET-induced signaling and cell growth and to establish whether growth suppression is enhanced by co-targ… (full text at CIViC) PMID 23828865 · Gild et al., 2013 · Open in CIViC	civic

Thyroid Gland Carcinoma1

RET Mutation

NVP-AST487 + SapanisertibCombination

Predictive

Supports Sensitivity Response

submitted

EID4854

The objective of this preclinical study was to investigate the contribution of mTOR activity to RET-induced signaling and cell growth and to establish whether growth suppression is enhanced by co-targ… (full text at CIViC)

PMID 23828865 · Gild et al., 2013 · Open in CIViC

civic

Thyroid Gland Medullary Carcinoma5
RET Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID74 In a study of 100 patients with sporadic medullary thyroid carcinoma (MTC), RET gene exons 10-11 and 13-16 were analyzed with tumor and matched normal samples. A somatic RET mutation was identified in… (full text at CIViC) PMID 18073307 · Elisei et al., 2008 · Open in CIViC	civic
RET Mutation	Cabozantinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID8984 In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and… (full text at CIViC) PMID 27525386 · Sherman et al., 2016 · Open in CIViC	civic
RET Mutation	Selpercatinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID8851 In this international phase 1/2 trial (NCT03157128), 55 RET-mutant medullary thyroid cancer patients who had previously received the multi-kinase inhibitors vandetanib and/or cabozantinib received th… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC	civic
RET Mutation	Selpercatinib	Predictive	A	Supports Sensitivity Response	5	accepted	EID12157 In this phase III trial, 291 patients (12 years or older) with medullary thyroid cancer harbouring RET mutations were enrolled. Patients were randomized in a 2:1 ratio to receive selpercatinib (n=193)… (full text at CIViC) PMID 37870969 · Hadoux et al., 2023 · Open in CIViC	civic
RET Mutation	Selpercatinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID7070 In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Tumor reduction was achieved in 79% of medullary th… (full text at CIViC) Open in CIViC	civic

Thyroid Gland Medullary Carcinoma5

RET Mutation

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID74

In a study of 100 patients with sporadic medullary thyroid carcinoma (MTC), RET gene exons 10-11 and 13-16 were analyzed with tumor and matched normal samples. A somatic RET mutation was identified in… (full text at CIViC)

PMID 18073307 · Elisei et al., 2008 · Open in CIViC

civic

RET Mutation

Cabozantinib

Predictive

Supports Sensitivity Response

submitted

EID8984

In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and… (full text at CIViC)

PMID 27525386 · Sherman et al., 2016 · Open in CIViC

civic

RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID8851

In this international phase 1/2 trial (NCT03157128), 55 RET-mutant medullary thyroid cancer patients who had previously received the multi-kinase inhibitors vandetanib and/or cabozantinib received th… (full text at CIViC)

PMID 32846061 · Wirth et al., 2020 · Open in CIViC

civic

RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID12157

In this phase III trial, 291 patients (12 years or older) with medullary thyroid cancer harbouring RET mutations were enrolled. Patients were randomized in a 2:1 ratio to receive selpercatinib (n=193)… (full text at CIViC)

PMID 37870969 · Hadoux et al., 2023 · Open in CIViC

civic

RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID7070

In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Tumor reduction was achieved in 79% of medullary th… (full text at CIViC)

Open in CIViC

civic

Evidence by cancer (10 items)

Clinical significance (0)